You are here

Mikolaj Slabicki

Publications

Nitsch L, Jensen P, Yoon H, et. al. BTBBCL6 dimers as building blocks for reversible drug-induced protein oligomerization. Cell Rep Methods. 2022;2(4):100193. Published 2022 Apr 13. doi:10.1016/j.crmeth.2022.100193

Słabicki M, Yoon H, Koeppel J, et al. Small-molecule-induced polymerization triggers degradation of BCL6. Nature. 2020;588(7836):164-168. doi:10.1038/s41586-020-2925-1

Słabicki M, Kozicka Z, Petzold G, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature. 2020;585(7824):293-297. doi:10.1038/s41586-020-2374-x

Mikolaj Slabicki, Ph.D.

Mikołaj Słabicki is a group leader in the Cancer Program and a member of Benjamin Ebert’s laboratory at the Broad Institute of MIT and Harvard. He is also a senior staff scientist at the Dana-Farber Cancer Institute. He employs functional genomics, high-throughput screening, chemical biology, cell biology, and biochemical techniques to identify and characterize new molecular glue degraders and novel mechanisms of targeted protein degradation.

Słabicki’s research expanded the repertoire of molecular glue degraders and showed that the CDK inhibitor, CR8, induced degradation of cyclin K without a canonical substrate receptor. He is also a founding co-organizer of the Dana-Farber Targeted Protein Degradation webinar series that features biweekly talks from experts in the field.

Słabicki graduated with an M.S. in biotechnology from the Technical University of Łódź, in Poland. During his graduate studies in Frank Buchholz's lab at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, Słabicki employed functional genomics to study the mechanism of double-stranded DNA breaks and characterized a novel hereditary spastic paraplegia gene, SPG48. He identified CREM, MBD2, and CHD4 as novel CD20 modulators during his postdoctoral research as a Marie Skłodowska Curie Scholar in Benjamin Ebert’s laboratory at the Dana-Farber Cancer Institute in Boston, United States, and in Stefan Fröhling’s laboratory at the German Cancer Research Center in Heidelberg, Germany.

November 2022